We scan new podcasts and send you the top 5 insights daily.
Roche expanded its Hansa Pharmaceutical partnership with $400 million upfront and $110 million due on the first anniversary. Hansa will advance multiple antibody-drug conjugates through Phase I before Roche takes over outside Greater China; the deal carries up to $15 billion in milestones. Roche had already struck an ADC deal last year.
Western pharma firms strategically license assets from Chinese biotechs while leaving China rights with the local partner. This leverages China's faster, cheaper clinical development, as the partner tests the molecule in new indications, generating valuable data that de-risks the asset for the global firm at no extra cost.
A notable trend is the licensing of advanced clinical assets from Chinese biotechs to major global pharmaceutical companies for ex-China rights. Deals like Roche licensing Medilink's Phase 3 ADC and AbbVie licensing Reamgen's Phase 2 bispecific antibody signal China's evolution from a market to a source of high-value, late-stage innovation.
Major pharmaceutical companies are committing to bio-buck deals worth billions for unproven, preclinical assets. The Sanofi-Irindale deal ($2.56B potential) and the Pfizer-Cartography deal ($850M+ potential) for discovery-stage programs show a high appetite for risk when accessing innovative technology platforms and novel targets early on.
Historically, multinational drugmakers sourced clinical-stage oncology antibodies and antibody-drug conjugates from China. Recent multibillion-dollar transactions from Novartis, Merck, and Novo Nordisk signal a shift toward acquiring preclinical-stage assets across diverse disease areas and novel modalities—such as mRNA-encoded T-cell engagers and molecular glues—demonstrating increasing Western confidence in early-stage, potentially first-in-class Chinese discovery.
A trio of significant deals in one week—Novo Nordisk, Merck, and Novartis all partnering with Chinese biotechs—underscores a major trend. Western pharmaceutical giants are now aggressively sourcing early-stage, preclinical assets from China to fuel their global R&D pipelines.
In a dramatic shift from manufacturing to innovation, Chinese biopharma's share of global out-licensing deals (valued over $50M) has exploded. It grew from just 5% five years ago to 30% last year, and has already hit 42% in the first half of the current year, attracting massive investment from Western giants.
The Simcirzyming and Ipsen deal, valued up to $1.06 billion for a preclinical antibody-drug conjugate (ADC), shows the immense value of promising therapeutic modalities. Technologies like ADCs with features like 'enhanced tumor penetration' can secure massive bio-dollar deals long before human trials, signaling intense competition for next-generation oncology assets.
The Sino Biopharmaceutical and Sanofi deal for rovodicitinib, a drug already approved in China, signals a key trend. Chinese biotechs are now developing and securing domestic approval for novel assets before out-licensing them for global commercialization, commanding significant upfront payments and billion-dollar milestone potentials.
In a major strategic shift, large pharmaceutical companies are increasingly sourcing their M&A pipeline from China. Chinese assets now account for 30-40% of Big Pharma's early-stage acquisitions, up from single digits just a few years ago, primarily because they are significantly cheaper than US or European equivalents.
Roche paid $400 million upfront, plus $115 million on the first anniversary, for ex-China rights to two preclinical ADCs and $15 billion in milestones. Stephen Hansen notes Novartis, Novo and Merck recently signed similar early China deals; Jeff Cranmer says Hanso will run Phase 1A before Roche takes over.